

Provided by the author(s) and University of Galway in accordance with publisher policies. Please cite the published version when available.

	"Waiting for Science to Catch up with Practice": an examination of 10-year YouTube trends in discussions of
Title	chronic cerebral spinal venous insufficiency treatment for multiple sclerosis
Author(s)	Hynes, Sinéad M.; Ghahari, Setareh; Forwell, Susan J.
Publication Date	2019-03-26
Publication Information	Hynes, Sinéad M., Ghahari, Setareh, & Forwell, Susan J. (2019). "Waiting for Science to Catch up with Practice": an examination of 10-year YouTube trends in discussions of chronic cerebral spinal venous insufficiency treatment for multiple sclerosis. Informatics for Health and Social Care, doi: 10.1080/17538157.2019.1582052
Publisher	Taylor & Francis
Link to publisher's version	https://doi.org/10.1080/17538157.2019.1582052
Item record	http://hdl.handle.net/10379/15072
DOI	http://dx.doi.org/10.1080/17538157.2019.1582052

Downloaded 2024-04-26T20:03:13Z

Some rights reserved. For more information, please see the item record link above.



- 1 **Title:** "Waiting for Science to Catch up with Practice": Examination of ten-year YouTube
- 2 trends in discussions of chronic cerebral spinal venous insufficiency treatment for multiple
- 3 sclerosis.
- 4 Running Head: YouTube Discussions of CCSVI Treatment for MS
- 5 **Authors:** Sinéad M. Hynes, PhD, BSc (Hons); Setareh Ghahari, PhD, MSc, BSc; Susan J.
- 6 Forwell, PhD, OT(C), FCAOT.
- 7 Affiliations:
- 8 Sinéad M. Hynes; Discipline of Occupational Therapy, College of Medicine, Nursing and
- 9 Health Sciences, Áras Moyola, National University of Ireland, Galway, Ireland.
- 10 Setareh Ghahari; School of Rehabilitation Therapy, Queen's University, Kingston, Canada;
- 11 Department of Occupational Therapy, University of Social Welfare and Rehabilitation
- 12 Sciences, Tehran, Iran.
- 13 Susan J. Forwell; Department of Occupational Science and Occupational Therapy, University
- of British Columbia, Vancouver, Canada.
- 15 **Correspondence:** Sinéad Hynes, PhD; Phone: +4435391495624, Email:
- sinead.hynes@nuigalway.ie

#### **ABSTRACT**

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

Objective: The objective of this longitudinal study examined, first, whether people with multiple sclerosis who previously advocated for angioplasty to treat chronic cerebral spinal venous insufficiency (CCSVI) through YouTube continued reporting benefits. Second, it examined a new cohort reporting on CCSVI treatment; and third, whether perspectives have changed. Method: YouTube videos from August 2011 to January 2019 related to CCSVI were retrieved. Once retrieved, all videos were compiled, classified and analysed. Categorical data were reported and a pre-determined code-book was used to code videos. Data from the videos were extracted and analysed using discourse analysis. Results: 1293 videos related to CCSVI were uploaded by 54 people with multiple sclerosis who met the inclusion criteria. YouTube videos uploaded by people with multiple sclerosis have shifted in volume and message. The initial surge in interest in CCSVI treatment has diminished, but there still exists strong advocates for its use. There appears to be inconsistency between positive results, actual improvements in symptoms, and the overall messages reported. Very little long-term data was available as the procedure is relatively new. Conclusion: Practitioners may be faced with pressure to provide unproven treatments in future and should be understanding but evidence-driven when supporting multiple sclerosis therapies.

#### INTRODUCTION

37

Multiple sclerosis (MS) is a progressive demyelinating disease of the brain and spinal cord 38 [1] and is the most common neurological condition that has a disabling effect on young and 39 40 middle-aged adults [2]. There is currently no known cure for MS. Interventions used to treat MS are typically pharmaceutical therapies and behavioural strategies. The pharmaceutics are 41 42 used for relapse management (the mainstay of which is corticosteroids; [3]), to minimize the course of the disease (using a number of injectable and oral disease modifying therapies), and 43 to manage symptoms of MS (such as fatigue, spasticity, and urinary problems). The 44 45 behavioural interventions focus on remedial, adaptive and self-management techniques to support daily function. None of the treatments, however, halt the progression or offer a cure 46 for MS. As a result, people are looking to alternative beneficial treatments. 47 48 In 2009, it was proposed by Zamboni et al. [4] that MS may be caused by, or significantly associated with, stenosis of the extracranial venous drainage system- known as chronic 49 cerebrospinal venous insufficiency (CCSVI). It was suggested that percutaneous transluminal 50 angioplasty of the extracranial veins that treated CCSVI was an effective alternative 51 treatment for MS – even go as far as terming it "Liberation treatment". To support this 52 53 alternative treatment, Zamboni et al. [5] carried out an unblinded and uncontrolled trial of CCSVI treatment and reported improved quality of life and disability status in persons with 54 55 MS. This research received unprecedented media attention and had been referred to as a 56 "medical miracle" by health professionals and patients alike [6]. Since this first study there 57 have been over 100 studies [7-10] undertaken to determine the efficacy of the angioplasty treatment for CCSVI and its impact on MS. Despite the lack of clear evidence of 58 59 effectiveness, CCSVI-related interventions were offered by private hospitals and clinics globally to people willing and able to pay the costs. Procedures took place outside of clinical 60 trials and resulted in a number of side-effects and significant safety concerns [11]. Social 61

62 media discussions, campaigns and pressure on the topic were tremendous [12]. Calls for clinical trials and strong lobbying by patients, especially in British Columbia, Canada where 63 the prevalence of MS is very high, [13; 14] resulted in government and private donor funded 64 trials of CCSVI treatment. 65 In a review of the literature on CCSVI and MS, Tsivgoulis et al. [7] found that the majority of 66 studies failed to reproduce the high prevalence of CCSVI in MS initially reported [5]. 67 Tsivgoulis et al. [7] were critical of what they called a "poorly reproducible and clinically 68 irrelevant sonographic construct" (pp: 8) and provided very clear recommendations from 69 70 their review: "Liberation treatment' has no proven efficacy, may exacerbate underlying disease 71 activity and has been complicated with serious adverse events. 'Liberation treatment' 72 should stop being offered to MS patients even in settings of randomised controlled 73 trials, while further unnecessary expenditure of scares funding resources needs to be 74 discontinued" (pp:8). 75 They recommended instead that clinicians speak to their patients about the dangers of CCSVI 76 treatment and its lack of efficacy. They reported that the sensationalising of the treatment had 77 led to many patients receiving an unnecessary and invasive treatment. Since then, Traboulsee 78 and colleagues [15] conducted an assessor-blinded, case-control, multicentre study and found 79 80 no link between MS and CCSVI. They used catheter venography (CV), thought to be more sensitive and specific than the ultrasound criteria used by Zamboni et al. [5]. Specifically, 81 they found that 2% of people with MS, 2% of unaffected siblings, and 3% of unrelated 82 83 controls tested positive for CCSVI. Overall findings of the trial [16], do not support the CCSVI theory. They found no difference between controls and people with MS in terms of 84 narrowed neck veins. They also reported that compared to CV, magnetic resonance 85

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

venography has poor interobserver agreement and poor specificity. Siddiqui et al. [17] reported results of a safety and efficacy double-blinded trial of venous angioplasty in people with MS. They concluded that the intervention was not effective and should not be used as it may exacerbate underlying disease activity. Bourdette and Cohen [18] echoed the sentiment of Tsivgoulis et al. [7] and Siddiqui et al. [17], and referred to the venous angioplasty for treatment of MS as an "ineffective treatment that is based on an incorrect theory" (pp:388). Regardless of the results of the trials, the significant lobbying efforts and the ability to gain momentum was partly made possible by social media, and demonstrates the power and influence of social media on current research priorities [12, 19]. Ghahari and Forwell [20] examined the social media movement (specifically on http://www.youtube.com) for messages regarding CCSVI treatment. The study was initiated immediately following the 2009 airing of an episode about CCSVI on "The Fifth Estate", a weekly television programme on the national broadcaster Canadian Broadcasting Centre (CBC). The authors reviewed YouTube videos for the period of December 2009 to July 2011, and found that strong positive views were reported by people with MS. Furthermore, they found that health professionals who were commenting on the procedure were largely positive in their reports. They also observed that the initial burst of positivity towards the treatment was maintained to the end of the study period of 2011. There appears to be limited examination or follow-up on the current views of people with MS regarding the treatment, given the overwhelming evidence against its use [19]. This is important given the influence that social media reports can have on patients – social media is being used more and more for supplementing information provided by health care professionals and for interacting with peers about health-related concerns.[21]. This study, therefore, aimed to understand the view of patients about CCSVI since 2011. This study is important for health professionals in order to be aware of current health care trends with patients with MS.

The objective of the study was to determine if people with MS continue to report benefits of CCSVI treatment on YouTube, and if perspectives have changed. We had two key research questions.

- 1. What message was conveyed through YouTube on CCSVI and its treatment?
- 2. How does this message and volume of videos being uploaded compare to the previous study [20]?

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

111

112

113

114

115

116

#### **METHODS AND PROCEDURES**

This study used a longitudinal design. Data was collected from YouTube between August 2011 and January 2019. YouTube was selected as the preferred social media platform as it allows for the examination of videos of varying lengths, it can be used to track progress if multiple videos are uploaded over time and it is free to use and to upload onto. Using videos over written testimonials (e.g. blogs) allows for more objective measure of function, although caveats to this exist as it is still possible to falsely report through the medium of video. This research is primarily quantitative in nature but includes aspects of qualitative methodology used to analyse messages in the videos collected. For the data collection the methodology from Ghahari and Forwell [20] was used. This was to allow for comparisons between the datasets. First, data from videos were collected. This included all data presented in the video – visual, audio and written information. Second, the collected data were classified using a pre-defined codebook (see data analysis for details). Third, the dominant messages from the collected data were extracted using the discourse analysis. Unlike Ghahari and Forwell [20] who looked at people with MS and HCP, here we only interested in the perspective of people with MS, because they were driving the demand for

135 research and treatment of CCSVI. For this reason, only videos uploaded by people with MS were included. 136 137 Data collection 138 All videos were sourced through http://www.youtube.com/ between August 2011 and January 139 2019. Search terms included "CCSVI", "chronic cerebral spinal venous insufficiency", 140 "liberation therapy", "liberation and MS", "Zamboni treatment" or a combination. 141 To answer our research questions, we conducted a rigorous review in order to collected two 142 143 sets of data. 1. Set 1- a search was carried out for videos uploaded between August 2011 to 144 January 2019 by persons with MS (n=224) who had previously uploaded 145 videos from November 2009 to July 2011 as identified by Ghahari and 146 Forwell [20] dataset. 147 148 2. Set 2- we searched for videos uploaded by persons with MS who had uploaded videos between August 2011 and January 2019 but were not in dataset by 149 Ghahari & Forwell [20]. 150 Inclusion criteria: All included videos had pre and post CCSVI treatment results; included 151 person with MS; and were in English. 152 Exclusion criteria: Videos were not included if they were conference proceedings, television, 153 radio programmes or promotional videos, or were uploaded by patients who were also 154

We searched the dataset from Ghahari and Forwell [20] (n=224) on YouTube for new videos that had been uploaded since the previous study [20] ended (August 1st 2011- January 30th

2019). We found 52.7% (118) of people had not uploaded new videos related to CCSVI, or

specialists, as no health professional videos were included.

155

had removed the videos that were previously available to view, or made them private. 106 people had uploaded (at least one) new video after August 2011.

Through coding of the videos for the 106 people, another 76 were excluded for reasons such as the videos being a public presentation, or about a different treatment (see Figure 1). Only videos describing patient progress following CCSVI treatment were included, leaving a total of 30 videos (from 30 people). This constituted set one data. Some people had uploaded multiple videos (range 1-67) but in order to have equal representation from each person the last video uploaded was chosen for extraction and analysis in the case of multiple uploads (one video per person).

#### [Insert Figure 1 approximately here]

Set two data included videos uploaded by persons with MS who had not previously uploaded videos prior to July 2011. Videos uploaded from August 1, 2011 to January 30, 2019 were extracted. The total search results provided 669 videos, of which 645 videos were excluded for the following reasons: 273 were not in English; six were not related to CCSVI/MS; four persons did not have MS; 276 were conference proceedings/ promotional videos (210 conference proceedings were reported in the study by & Forwell [20]); seven were outside of the time of the search; 12 had no information given on pre/post CCSVI; 43 were duplicate videos; seven were television/radio programmes; and 17 were multiple uploads.

This search left a final sample of 24 videos (from 24 people; one video per person was extracted for analysis to allow for balanced representation) related to patient experience of

#### Instrument

CCSVI treatment.

Videos were coded using a pre-defined codebook. The codebook was developed based on that used by Ghahari and Forwell [20]. The codebook was pilot tested on 10% of videos. After the pilot and discussion between the raters, the codebook was adapted for use in this study. It consisted of a list of 29 individual symptoms. If the codes were reported by less than two person with MS they were collapsed into one category and coded as "Other". Coding by symptom was categorised as "Decrease in function", "Improvement", "No change/fluctuation", "Not reported" as it was evident from watching the video. Other details such as time since angioplasty procedure, whether the person had multiple procedures, mobility status, change in work status or leisure participation were recorded. Raters were asked to rate the overall message in the video as "Positive", "Negative", "Neutral" or "None of the Above" and to provide a statement by the person with MS to justify this. Inter-rater reliability between the two raters was assessed on 20% of videos at the beginning of the analysis process. The percent agreement statistic is reported here as it is directly interpretable. We acknowledge its limitation in not accounting for the possibility that raters guessed on scores which may lead to an over-estimation of the true agreement [22]. Taking that into account it has been recommended as being a reliable determinant of interrater reliability when raters are well trained and little guessing is likely to exist [22] which is true here. We set a minimum acceptable level at above 75% agreement with 90% being considered high [23]. Agreement of 94% was achieved here and was considered high.

201

202

203

204

205

206

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

#### Data analysis

Once all videos were extracted they were compiled and analysed as one group (set one + set two). Categorical data relating to video length and number of uploads were entered into and analysed using SPSS (IBM, version 22). Comparisons with videos by Ghahari and Forwell [20] was also carried out using SPSS.

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

Two raters were involved in the analysis of the videos. One rater had no background knowledge of MS and the other rater was a researcher who was a health care professional. Messages from the videos were analysed using discourse analysis [24; 25] in order to identify the overarching messages within the videos. Discourse analysis was used in the previous study [20] and was shown to be an effective method for approaching data from social media as it allows for individual and group/public discourse. The use of language is of concern and an interpretative analysis of the data took place [25] in order to find themes within the video data. Ethical Approval: This study was exempt from ethical approval as all data used was publicly available and no data was directly collected from participants. **RESULTS** This study included 30 videos in set one and 24 videos in set two, giving a total of 54 videos (from 54 people). Key Messages in the videos Sixty-three percent (34) of videos by persons with MS gave a positive report of the treatment, 13% (7) were negative, 13% (7) videos did not provide a clear opinion on the treatment and 11% (6) of videos did not provide a view. Following CCSVI treatment, 8% people had returned to full-time work/education; 2% had returned to part-time work/education; and 90% did not report on this. No change in leisure activities was reported by 84% of people, while 16% of individuals reported either taking up

new hobbies or being able to participate in hobbies they had not been able to enjoy for some time. The list of hobbies was as follows: working out, gardening, fishing, watching movies, holding pet birds, running, camping, cycling, and horse-riding. People did not always explain why they had not previously been able to participate in that leisure activity, e.g. watching movies. This aspect was not reported in the earlier study [20] but there was an improvement immediately (<1 month) post-CCSVI reported in 12.5% of people in the area of "Activity Participation" which may have encompassed leisure, work and education.

Changes in individual symptoms were reported by many people. Overall there were 29 symptoms listed in the codebook. Of these only eight symptoms were reported by two or more people, as well as reports of whether an increase in function, decrease in function or no change was reported. These results are shown in Table 1.

#### [Insert Table 1 approximately here]

The most common symptoms that were reported to have improved were overall health, balance, strength and stiffness; while interestingly they were also the most commonly reported symptoms to have worsened. People also noted how they were mobilising but it was not always clear if this signified an increase or decrease in function, or if there had been no change. 26% of people were mobilising independently, 8% reported running, 6% were using a cane, 10% were using a wheelchair, 10% were using a walker and 40% did not report how they were get around.

#### Changes in volume and characteristics of videos

During the study period of 89 months and an average of 0.61 people with MS uploading CCSVI videos each month. Ghahari and Forwell [20] had 224 persons with MS uploading

279

[26]

256 videos over 22 months which was 10.18 people each month uploading CCSVI videos. This equates to a decrease of 94% in the number of people uploading videos in the current study 257 compared to in Ghahari and Forwell [20]. 258 A total of 399 videos had been uploaded by the 54 people included in the study. These 259 persons with MS uploaded a mean of 7.39 videos (SD 12.2) each with a range of 1-67 videos 260 261 uploaded by each person as shown in Figure 2. 262 [Insert Figure 2 approximately here] 263 264 The mean time between uploading their first and last CCSVI video was 558.3 days (SD 265 611.8). The standard deviation here indicates quite a large variance in the length in time with 266 a range of between 0 (for people who only uploaded one video) and 2920 days. Some people 267 had uploaded their CCSVI video on the day that they had their surgery while others, the 268 video was uploaded much later (range 0-1465 days). The mean time since CCSVI treatment 269 was 535.9 days (SD 488.4). The average length of each video was 7 minutes 12 seconds with 270 a range of 53:16-01:14. 271 272 Describing the CCSVI experience 273 Although the majority (63%) of the reports of CCSVI treatment were positive, the overall 274 commentaries were often conflicting and not always supportive of the treatment. It is also 275 evident that even the comments that are unsupportive of the treatment continue to have a 276 277 positive spin, as demonstrated in the following: "I haven't been able yet to experience the fabulousness that I know is going to come". 278

280	This optimistic view of the treatment was also seen in a number of people who reported
281	positively on their second treatment, even if the results from the first treatment were quite
282	poor. Some people reported on their initial improvement of function, even when this was
283	followed by a gradual decrease in function.
284	There were comments related to the treatment that could not be categorised as "positive" or
285	"negative". This was the case when a video reported no change. One person described the
286	period following her treatment as:
287	"The best six months of my life but as we know people are re-stinosing". [27]
288	This indicates that she had positive results but they were short-lived. There was some caution
289	reported, emphasising that the treatment might not be effective for everyone:
290	"Obviously the biggest caveat to the whole thing is that it does not work for
291	everybody but for those that it does, it brings hope into a pretty bleak future when all
292	else has failed." [28].
293	Not all people with MS provided commentary on their view of their improvements, some just
294	videoed themselves completing various tasks or exercises.
295	Of the 54 videos, 16% had a second angioplasty procedure and 4% had a third or fourth
296	procedure, while 34% were recommending alternative treatments (see Table 2). The most
297	common treatments were related to either changing diet (suggested in six videos) or having a
298	stem cell transplant (suggested in five videos).
299	
300	[Insert Table 2 approximately here]
301	

DISCUSSION

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

The objective of this study was to examine what message is being conveyed through YouTube on CCSVI and its treatment and how this compares to previous research [20]. The study results found a change in the volume of messages being uploaded on the topic but not necessarily a change in the message being conveyed. The messages on the topic do, however, appear to be more moderated in comparison to the previous study [20]. We found a rather conflicting message regarding CCSVI treatment, as presented by people with MS on YouTube. There are still positive results being reported about CCSVI treatment by the YouTube users with MS who were included in this study. Viewed alone, this would suggest positivity about this treatment still exists after ten years since this treatment first received its publicity in both scientific and popular media [4, 5]. There are, however, many other factors to consider before making such assumptions. The first thing to consider is the volume of videos being uploaded has decreased significantly - 94% fewer videos can be found online in recent years of people with MS who are reporting on their CCSVI treatment than before August 2011 [20]. Prior to when this search was conducted CCSVI was a very hot topic, such that public interest in the treatment grew rapidly during the first year [12]. As with all new trends, a fall-off in interest is to be expected but as this particular movement had such a powerful following and strong online presence it is striking that this fall-off has been so significant. There are several suggestions as to why this may be. It could be that people campaigning for trials in CCSVI have had their requests granted. Randomised controlled trials of the treatment are being conducted in numerous locations, including a multi-centre trial of balloon angioplasty in Canada (ClinicalTrials.gov Identifier: NCT01864941) [29] which was largely due to strong public pressure. People may be satisfied that their views have been considered and acted upon and no longer see the need to use social media as a campaigning tool.

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

Another reason why there may be fewer videos being uploaded may be that people who have had the treatment have stopped uploading videos as they are now too busy in their daily lives to be making videos like before. This, however, does not account for the drop in before/after videos as this should also have been the case when the treatment was new, circa 2009. It may justify the lack of videos reporting long term benefits of treatment, since people may not want to spend time reporting on their treatment as they are living their lives. There are very few videos reporting on the results of CCSVI treatment two years or more post-surgery. This could also be because the results have not been encouraging and people may be less likely to report on negative results. If this was the case then it would be similar to the results of clinical trials that have been reported on to date [17]. It may also be that given the results of RCTs, patients are not putting themselves at undue risk by having the procedure. Bourdette and Cohen [18] go so far as to recommend the end of all investigations of the treatment as they are confident that it is ineffective and it is "placing participants at risk of complications without a reasonable hope of benefit" (pp: 388). Now that the data exists it is likely that people are considering the results when making health decisions. Secondly, although 63% of comments made by people with MS about specific symptoms are positive, the overall comments in many cases are contradictory and not supportive of treatment. People reported on the benefits that they derived from the treatment but this was often followed by a statement indicating that the benefits were no longer present. Similar to the results seen here, in a group of participants in Canada interviewed 24 months post-surgery there was an initial reporting of improvements but these improvements were reported not to have been sustained over time [30]. Additionally 11% of participants reported complications during the surgery and a further 17% reporting complications within a month of surgery. In this study we found very little discussion around safety when people spoke about their experience of the treatment or their decision to have it. In the previous study [20] people were

352 in fact mentioning safety concerns following the news of the deaths of two Canadians who had the procedure. There has, in more recent research, been some discussion around the risks 353 associated with the treatment by patients themselves [30]. 354 Interestingly, health, balance, strength and stiffness were both the most commonly reported 355 symptoms to improve and worsen following CCSVI treatment. This suggests that CCSVI is 356 not having consistent effects on people's health. Expectations of the treatment do seem to 357 have diminished somewhat and there is more caution when people are reporting on results. 358 Although 63% of people have reported improvements in function in the current study, this is 359 360 down from 86% found by Ghahari and Forwell [20]. Finally, other treatments are now being suggested by people either in combination with or instead of CCSVI treatment. Some of the 361 suggested treatments are invasive (e.g. stem cells) but several are not (e.g. exercise and diet 362 change). 363 As is the case with any study of this nature, there are inherent limitations to the generalisation 364 of the findings. It is important to keep in mind that what is being reported on is data obtained 365 from YouTube videos reporting on CCSVI treatment for MS. We do not claim that these 366 results are reflective of all people who have had the treatment or that they report on the 367 effectiveness of the treatment. We are reporting solely on the trends in YouTube discussions 368 around CCSVI treatment and MS on YouTube. 369 Some of the challenges that come with this type of research include difficulties with carrying 370 out accurate searches as videos may be removed or made private and restrictions exist on the 371 website for filtering irrelevant material. Also, reporting bias cannot be controlled for. There 372 appeared to be a positive reporting bias in the videos that were uploaded, since many videos 373 (which did not meet our inclusion criteria) were labelled "Pre-CCSVI" but were not 374 followed-up with "Post-CCSVI" videos. There could be a number of reasons for this but the 375

pressure to report positively or not report at all could have been a key factor here. Missing data is a limitation of this type of research as people are reporting on many different issues. Having consistent data and getting clear answers to the research questions of interest is not possible with this type of retrospective study. It is also not possible to carry out a formal analysis of the commentaries given by people as no interview schedule was followed, and if attempted, data could be easily skewed. Given the limitations of this study it was important that a consistent approach to analysis was taken and an analysis plan that included development of a codebook, which ensured high inter-rater reliability, was followed by authors prior to beginning analysis.

#### **CONCLUSION**

While YouTube videos uploaded by people with MS have shifted in volume and, to some extent, message, it appears that at least online the debate regarding this controversial procedure continues. The impact of these discussions for HCP and people with MS needs to be acknowledged in light of the availability of risky treatments abroad. Longer-term results of CCSVI treatment have been scant and for many disappointing, but positive short-term results are still being reported by YouTube users.

Although the focus here was on the YouTube platform, various forms of social media appear to play a key role in health decision making for many people with MS. Health care professionals need to be aware of this and encourage debate and discussion around treatment options with patients. They may be faced with pressure by patients to provide unproven or experimental treatments in the future. It is important that health care professionals be understanding of the patient perspective but also evidence-driven when supporting therapies in MS.

400	
401	DISCLOSURE OF INTEREST
402	The authors report no conflicts of interest.
403	
404	ACKNOWLEDGEMENTS
405	This research is funded in part by a National MS Society Post-doctoral Fellowship Award
406	No. MB 0016.
407	Thanks to Amy Villablanca who assisted with the study through data cleaning and analysis of
408	videos. Thank you to Sara Morassaei for her helpful comments on the paper.
409	

### 410 **REFERENCES** 1. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD et al. 411 Disease modifying therapies in multiple sclerosis: Subcommittee of the American 412 413 Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology, 2002; 58(2): 169-178. doi:10.1212/WNL.58.2.169 414 415 2. Barten LJ, Allington DR, Procacci KA, & Rivey MP. New approaches in the management of multiple sclerosis. Drug design, development and therapy. 2010; 4: 416 343. 417 418 3. Murray TJ. Diagnosis and treatment of multiple sclerosis. British Medical Journal. 2006; 7540:525. 419 4. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G, Dall'Ara S et al. 420 421 Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 2009; 80:392–399. 422 doi:10.1136/jnnp.2008.157164 423 5. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Gianesini S, Bartolomei I et al. A 424 prospective open-label study of endovascular treatment of chronic cerebrospinal 425 venous insufficiency. Journal of Vascular Surgery, 2009; 50(6): 1348–58.e1–3. 426 doi:10.1016/j.jvs.2009.07.096 427 6. Munkres B. Pitch for funding—living through a miracle—a documentary about 428 429 CCSVI. YouTube website. https://www.youtube.com/ watch?v=gMCzmP3y7Zg. Updated July 11, 2011. Accessed December 10, 2014 430

sclerosis: a comprehensive meta-analysis of case-control studies. Therapeutic advances in neurological disorders. 2013; 1756285613499425.

Psaltopoulou T et al. Chronic cerebrospinal venous insufficiency and multiple

7. Tsivgoulis G, Sergentanis TN, Chan A, Voumvourakis K, Triantafyllou N,

431

432

433

435	8.	Zwischenberger BA, Beasley MM, Davenport DL & Xenos ES. Meta-analysis of the
436		correlation between chronic cerebrospinal venous insufficiency and multiple sclerosis.
437		Vascular and endovascular surgery. 2013; 47(8): 620-624.
438	9.	van Zuuren EJ, Fedorowicz Z, Pucci E, Jagannath VA, & Robak EW. Percutaneous
439		transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency
440		(CCSVI) in multiple sclerosis patients. Cochrane Database Syst Rev. 2012; 12.
441	10	. van Zuuren EJ, Fedorowicz Z, Pucci E, Jagannath V, & Robak EW. Percutaneous
442		transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency
443		in people with multiple sclerosis: a summary of a Cochrane systematic review.
444		Journal of Neurology, Neurosurgery & Psychiatry. 2014; 85(4): 405-410.
445	11	. Rudick RA. Multiple sclerosis: is multiple sclerosis caused by venous
446		insufficiency? Nature Rev. Neurol. 2010; 6: 472–474.
447	12	. Chafe R, Born KB, Slutsky AS & Laupacis A. The rise of people power. Nature.
448		2011; 472(7344): 410-411.
449	13	. Kingwell E, Zhu F, Marrie RA, Fisk JD, Wolfson C, Warren S, et al High incidence
450		and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings
451		from over two decades (1991–2010). Journal of neurology. 2015; 262(10): 2352-
452		2363.
453	14	. Poppe AY, Wolfson C, & Zhu B. Prevalence of multiple sclerosis in Canada: a
454		systematic review. The Canadian Journal of Neurological Sciences. Le Journal
455		Canadien Des Sciences Neurologiques. 2008; 35: 593–601.
456	15	. Traboulsee AL, Knox KB, Machan L, Zhao Y, Yee I, Rauscher A, et al. Prevalence of
457		extracranial venous narrowing on catheter venography in people with multiple
458		sclerosis, their siblings, and unrelated healthy controls: A blinded, case-control study.
459		The Lancet. 2014; 383(9912); 138–145. doi:10.1016/S0140-6736(13)61747-X

- 16. Martin N, Traboulsee AL, Machan L, Klass D, Ellchuk T, Zhao Y, Knox KB,
- Kopriva D, Lala S, Nickel D, Otani R. Prevalence of Extracranial Venous Narrowing
- on Magnetic Resonance Venography Is Similar in People With Multiple Sclerosis,
- Their Siblings, and Unrelated Healthy Controls: A Blinded, Case-Control Study.
- Canadian Association of Radiologists Journal. 2017 May 31;68(2):202-9.
- 17. Siddiqui AH, Zivadinov R, Benedict RH, Karmon Y, Yu J, Hartney ML et al.
- Prospective randomized trial of venous angioplasty in MS (PREMiSe). Neurology.
- 467 2014; 83(5): 441-449.
- 18. Bourdette DN, Cohen JA. Venous angioplasty for "CCSVI" in multiple sclerosis:
- ending a therapeutic misadventure. Neurology. 2014; 83(5):388-9.
- 19. Pullman D, Zarzeczny A, & Picard A. Media, politics and science policy: MS and
- evidence from the CCSVI trenches. BMC medical ethics. 2013; 14(1): 1.
- 20. Ghahari S & Forwell SJ. Social Media Representation: Chronic Cerebrospinal Venous
- Insufficiency for MS as an Example. International Journal of MS Care. 2015; 18(2):
- 474 49-57. DOI: 10.7224/1537-2073.2014-073
- 21. Benetoli A, Chen TF, Aslani P. How patients' use of social media impacts their
- interactions with healthcare professionals. Patient education and counseling. 2018
- 477 Mar 1;101(3):439-44.
- 478 22. McHugh ML. Interrater reliability: the kappa statistic. Biochemia medica: Biochemia
- 479 medica. 2012 Oct 15;22(3):276-82.
- 480 23. Chaturvedi SR. Evaluation of inter-rater agreement and inter-rater reliability for
- observational data: An overview of concepts and methods. Journal of the Indian
- Academy of Applied Psychology. 2015;41(3):20-7.
- 483 24. Wetherell M, Taylor S, Yates SJ, editors. Discourse as data: A guide for analysis.
- 484 Sage; 2001 May 25.


485	25. Gee, J. P., & Handford, M. (Eds.). (2013). The Routledge handbook of discourse
486	analysis. Routledge.
487	26. Judi. Judi's Update February 3 2014. YouTube website. 2014.
488	https://www.youtube.com/watch?v=gsZsVrtEVog. Accessed 20th January 2015
489	27. Mackierojo. CCSVI 2 Year Reflection. YouTube website. 2011.
490	https://www.youtube.com/watch?v=NozdueH9byU. Accessed: 16 <sup>th</sup> December 2014
491	28. Titlawhirl. 6 months CCSVI before after compilation. YouTube website. 2012.
492	https://www.youtube.com/watch?v=RhosV4_DvWw. Accessed: 19th January 2015
493	29. Interventional Clinical Trial for CCSVI in Multiple Sclerosis Patients:
494	https://clinical trials.gov/ct2/show/NCT01864941? term=Interventional+Clinical+Trials.gov/ct2/show/NCT01864941? term=Interventional+Clinical+Trials.gov/ct2/show/ct2/sh
495	+for+CCSVI+in+Multiple+Sclerosis+Patients&rank=1 (Accessed 18 <sup>th</sup> June 2015)
496	30. Sadovnick AD, Yee IM, Attwell-Pope K, Keyes G, Kipp L, Traboulsee AL. Patient-
497	Reported Benefits of Extracranial Venous Therapy: British Columbia CCSVI
498	Registry. Canadian Journal of Neurological Sciences. 2017 May;44(3):246-54.
499	
500	

**TABLE 1** Examples of symptoms being reported by people with MS in YouTube videos.

Symptom	Not reported	No Change	<b>Decreased function</b>	Improved function
Overall Health	24 (44%)	8 (15%)	7 (13%)	15 (28%)
Balance	34 (63%)	1 (2%)	5 (9%)	14 (26%)
Strength	37 (69%)	0 (0%)	6 (11%)	11 (20%)
Stiffness	39 (72%)	0 (0%)	5 (9%)	10 (19%)
Clear Head	47 (87%)	0 (0%)	3 (6%)	4 (7%)
Pain	42 (78%)	2 (4%)	4 (7%)	6 (11%)
Fatigue	41 (76%)	0 (0%)	4 (7%)	9 (17%)

# **TABLE 2** Alternative treatments being suggested by people with MS in YouTube videos.

Treatment	Number of videos	Details
Diet change	6	Vegan Diet
		Terry Wahl's Diet
		Paleo Diet
		Gluten-free Diet
Stem cell	5	Stem cell
Other	6	Acupuncture
		Exercise
		Medication change
Not reported	33	



### **FIGURE 2** Number of videos uploaded by person with MS in the study.

